» Articles » PMID: 10551817

P42/p44 Mitogen-activated Protein Kinases Phosphorylate Hypoxia-inducible Factor 1alpha (HIF-1alpha) and Enhance the Transcriptional Activity of HIF-1

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 1999 Nov 7
PMID 10551817
Citations 227
Authors
Affiliations
Soon will be listed here.
Abstract

Hypoxia-inducible factor-1 (HIF-1) controls the expression of a number of genes such as vascular endothelial growth factor and erythropoietin in low oxygen conditions. However, the molecular mechanisms that underlie the activation of the limiting subunit, HIF-1alpha, are still poorly resolved. Results showing that endogenous HIF-1alpha migrated 12 kDa higher than in vitro translated protein led us to evaluate the possible role of phosphorylation on this phenomenon. We report here that HIF-1alpha is strongly phosphorylated in vivo and that phosphorylation is responsible for the marked differences in the migration pattern of HIF-1alpha. In vitro, HIF-1alpha is phosphorylated by p42 and p44 mitogen-activated protein kinases (MAPKs) and not by p38 MAPK or c-Jun N-terminal kinase. Interestingly, p42/p44 MAPK stoichiometrically phosphorylate HIF-1alpha in vitro, as judged by a complete upper shift of HIF-1alpha. More importantly, we demonstrate that activation of the p42/p44 MAPK pathway in quiescent cells induced the phosphorylation and shift of HIF-1alpha, which was abrogated in presence of the MEK inhibitor, PD 98059. Finally, we found that in a vascular endothelial growth factor promoter mutated at sites previously shown to be MAPK-sensitive (SP1/AP2-88-66 site), p42/p44 MAPK activation is sufficient to promote the transcriptional activity of HIF-1. This interaction between HIF-1alpha and p42/p44 MAPK suggests a cooperation between hypoxic and growth factor signals that ultimately leads to the increase in HIF-1-mediated gene expression.

Citing Articles

Biomolecules Increase Glycolysis and Invasive Potential in Lung Adenocarcinoma.

Vega A, Shah P, Rouchka E, Clem B, Dean C, Woodrum N Cancers (Basel). 2025; 17(3).

PMID: 39941749 PMC: 11815989. DOI: 10.3390/cancers17030380.


HIF-1 and HIF-2 in cancer: structure, regulation, and therapeutic prospects.

Shi Y, Gilkes D Cell Mol Life Sci. 2025; 82(1):44.

PMID: 39825916 PMC: 11741981. DOI: 10.1007/s00018-024-05537-0.


HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.

Contenti J, Guo Y, Larcher M, Mirabal-Ortega L, Rouleau M, Irondelle M Cell Death Discov. 2024; 10(1):338.

PMID: 39048564 PMC: 11269614. DOI: 10.1038/s41420-024-02100-5.


The Role of Hyperbaric Oxygen Therapy in Neuroregeneration and Neuroprotection: A Review.

Barata P, Camacho O, Lima C, Pereira A Cureus. 2024; 16(6):e62067.

PMID: 38989389 PMC: 11235151. DOI: 10.7759/cureus.62067.


Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells.

Trejo-Solis C, Castillo-Rodriguez R, Serrano-Garcia N, Silva-Adaya D, Vargas-Cruz S, Chavez-Cortez E Metabolites. 2024; 14(5).

PMID: 38786726 PMC: 11122955. DOI: 10.3390/metabo14050249.